Pembrolizumab Phase 3 Trial for Urothelial Cancer Reaches Primary Completion

A Phase 3 clinical trial investigating pembrolizumab for localized muscle-invasive bladder cancer and locally advanced urothelial cancer reached its primary completion on 2026-06-01. This study enrolled 739 participants to evaluate the drug after surgery for these conditions.

Background

Pembrolizumab (Keytruda) is a monoclonal antibody that targets the PD-1 axis, a checkpoint molecule pathway. By blocking PD-1, pembrolizumab aims to enhance the patient's immune response to fight cancer. This trial specifically investigates its use in patients with localized muscle-invasive bladder cancer and locally advanced urothelial cancer, including those affecting the renal pelvis and ureter, after surgery.

Trial design

The Phase 3 study, identified as NCT03244384, is titled "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer". It enrolled a total of 739 participants. The trial is designed to evaluate pembrolizumab in patients with localized muscle-invasive bladder cancer and locally advanced urothelial carcinoma, including those affecting the renal pelvis and ureter, following surgical intervention.

What this means

The primary completion of this Phase 3 trial signifies that the main data collection period for the study's primary outcome has concluded. While this marks a significant milestone in the clinical development of pembrolizumab for these urothelial cancers, the actual results and efficacy data are not yet available. Clinicians, researchers, and patient advocates will need to await the release of the trial's findings to understand the potential role of pembrolizumab as an adjuvant therapy in this patient population after surgery.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03244384, titled "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer", was recorded with a primary completion date of 2026-06-01 on clinicaltrials.gov.